Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4864 - SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): results of Stage 1 - the non-randomised dose-finding component


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Pancreatic Adenocarcinoma


Somnath Mukherjee


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


S. Mukherjee1, P. Virdee2, R. Shaw3, J. Bridgewater4, G. Radhakrishna5, S. Falk6, M. Scott-Brown7, V.Y. Strauss2, C. Brooks3, R. Gillmore8, N. Patel9, B. Tranter10, P. Parsons11, D. Sebag-Montefiore12, M. Hawkins1, P.G. Corrie13, T.S. Maughan1

Author affiliations

  • 1 Oncology, Oxford Institute for Radiation oncology, OX3 7DQ - Oxford/GB
  • 2 Centre For Statistics In Medicine, Oxford University, Oxford/GB
  • 3 Oncology, Oncology Clinical Trials Office, Oxford/GB
  • 4 Oncology, University College London Hospitals, London/GB
  • 5 Oncology, Christie NHS Foundation Trust, Manchester/GB
  • 6 Bristol Haematology And Cancer Centre, Bristol University Hospitals NHS Foundation Trust, Bristol/GB
  • 7 Arden Cancer Centre, University Hospitals Coventry and Warwickshire, Coventry/GB
  • 8 Oncology, Royal Free London NHS Foundation Trust, London/GB
  • 9 Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford/GB
  • 10 Pharmacy, Velindre NHS University Trust, Cardiff/GB
  • 11 Velindre Cancer Centre, Velindre NHS University Trust, Cardiff/GB
  • 12 Gi Unit, University of Leeds, LS2 9LU - Leeds/GB
  • 13 Oncology Centre, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, CB2 0QQ - Cambridge/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4864


The anti-retroviral agent, nelfinavir, demonstrates radiosensitising effects in pre-clinical models of pancreatic cancer. The primary objective of Stage 1 was to establish the maximum tolerated dose (MTD) of nelfinavir combined with capecitabine-chemoradiation (CRT) after gemcitabine+nab-paclitaxel (GEMABX) induction chemotherapy.


Patients with inoperable, histologically/cytologically proven LAPC and WHO performance status 0-1 were eligible for this rolling-six dose-escalation stage. After 3 cycles of induction GEMABX (28-day cycle of nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1, 8, and 15), patients with non-progressive disease had 1 further cycle followed by CRT (50.4Gy/28 fractions, capecitabine 830mg/m2 bd on radiotherapy days) and 1000mg or 1250mg nelfinavir bd continuously during CRT. Other outcomes included overall survival and progression-free survival.


27 patients were recruited from 8 UK centres (March 2016-June 2017). Median age was 62 years, 30% were male, 78% had head tumours, and 30% had biliary stents. Baseline median tumour diameter was 36mm. 67% commenced CRT. 11 patients received 1000mg and there was one dose-limiting toxicity (DLT) in this group: grade 3 acute coronary syndrome. The nelfinavir dose was escalated as per the rolling-six design. 7 patients received 1250mg nelfinavir and no DLTs were observed. During GEMABX, common grade ≥3 toxicities among participants were neutropenia (30%), fatigue (22%), and diarrhoea (15%). During CRT, grade ≥3 toxicities included fatigue (6%) and anorexia (6%). No grade 5 adverse events were reported in Stage 1. Survival analysis will be presented.


1250mg nelfinavir was recommended for combining with capecitabine-CRT in the ongoing randomised component of the trial (Stage 2).

Clinical trial identification


Legal entity responsible for the study

University of Oxford, UK.


Cancer Research UK, Celgene.

Editorial Acknowledgement


S. Mukherjee, P.G. Corrie: Research funding: Celgene. J. Bridgewater: Consultancy: Celgene. N. Patel: Part-time employee of GSK. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.